cT1-4 N0M0 头颈部疣状癌的选择性颈淋巴结清扫术
该回顾性队列研究利用 2006 至 2017 年美国国家癌症数据库,分析 1015 例手术切除的 cT1-4 N0M0 头颈部疣状癌患者,其中 223 例(22.0%)接受选择性颈淋巴结清扫术(END)。END 仅检出 4.0% 的隐匿性淋巴结转移,且与观察组相比,5 年总生存率(71.3% vs 70.6%,p=.661)及 5 年死亡风险(调整后 HR 1.25,95%CI 0.91-1.71,p=.172)均无显著改善;结论认为 END 未带来明显生存获益。
要点
- 在 cT1-4 N0M0 头颈部疣状癌中,END 仅检出 4.0% 的隐匿性淋巴结转移。
- END 组与未行 END 组的 5 年总生存率分别为 71.3% 与 70.6%(p=.661),无显著差异。
- END 未显著降低 5 年死亡风险(调整后 HR 1.25,95%CI 0.91-1.71,p=.172)。
核心结论
- END 在头颈部疣状癌中未带来明显的生存获益,即使按多种患者、机构、肿瘤和治疗特征进行单因素和多因素分层分析后亦然。
研究设计与样本
- 回顾性队列研究,数据来自 2006 至 2017 年美国国家癌症数据库。
- 纳入 1015 例手术切除的 cT1-4 N0M0 头颈部疣状癌患者,其中 223 例(22.0%)接受 END。
主要发现
- END 检出隐匿性淋巴结转移的比例为 4.0%。
- 2006 至 2017 年,cT1-2 病变的 END 率从 16.3% 升至 22.0%(p=.126,R²=0.405),cT3-4 病变从 41.7% 升至 70.0%(p=.424,R²=0.232),趋势均未达统计学显著。
- 接受 END 的独立预测因素包括:在学术机构治疗(aOR 1.75,95%CI 1.19-2.55)、cT3-4 病变(aOR 3.31,95%CI 2.16-5.07)和肿瘤直径(aOR 1.09,95%CI 1.01-1.19)(p<0.05)。
- END 组与未行 END 组的 5 年总生存率分别为 71.3% 与 70.6%(p=.661)。
- END 未显著降低 5 年死亡风险(调整后 HR 1.25,95%CI 0.91-1.71,p=.172)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To investigate the survival benefit of elective neck dissection (END) over neck observation in cT1-4 N0M0 head and neck verrucous carcinoma (HNVC). STUDY DESIGN: Retrospective cohort study. SETTING: The 2006 to 2017 National Cancer Database. METHODS: Patients with surgically resected cT1-4 N0M0 HNVC were selected. Linear, binary logistic, Kaplan-Meier, and Cox proportional hazards regression models were utilized. RESULTS: Of 1015 patients satisfying inclusion criteria, 223 (22.0%) underwent END. The majority of patients were male (55.4%) and white (91.0%) with disease of the oral cavity (67.6%) classified as low grade (90.0%) and cT1-2 (81.8%). The minority of ENDs (4.0%) detected occult nodal metastases. The rate of END increased from 2006 to 2017 for both cT1-2 (16.3% vs 22.0%, p = .126, R2 = 0.405) and cT3-4 (41.7% vs 70.0%, p = .424, R2 = 0.232) disease but these trends were not statistically significant. Independent predictors of undergoing END included treatment at an academic facility (adjusted odds ratio [aOR]: 1.75, 95% confidence interval [CI]: 1.19-2.55), cT3-4 disease (aOR: 3.31, 95% CI: 2.16-5.07), and tumor diameter (aOR: 1.09, 95% CI: 1.01-1.19) (p < 0.05). The 5-year overall survival (OS) of patients treated with and without END was 71.3% and 70.6%, respectively (p = .661). END did not significantly reduce the 5-year hazard of death (adjusted hazard ratio: 1.25, 95% CI: 0.91-1.71, p = .172). END did not significantly improve 5-year OS in univariate and multivariate analyses stratified by several patient, facility, tumor, and treatment characteristics. CONCLUSION: END does not confer an appreciable survival benefit in HNVC, even after stratifying univariate and multivariate analyses by several patient, facility, tumor, and treatment characteristics. LEVEL OF EVIDENCE: Level 4.
引用
- Patel AM, Vedula S, Haleem A, et al. Elective Neck Dissection for cT1-4 N0M0 Head and Neck Verrucous Carcinoma. Otolaryngol Head Neck Surg. 2023. PMID: 37278222. doi:10.1002/ohn.374
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。